168 results about "Anticoagulant drug" patented technology

Compositions and methods for prevention and treatment of uncontrolled formation of intravascular fibrin clots, which are capable of selective dissolution of pathological nascent clots formed intravascularly, with minimal risk of unwanted dissolution of pre-existing hemostatic clots, are provided wherein fibrinolytic or anticoagulant drugs are biocompatibly coupled to red blood cell carriers.

Compositions and methods for prevention and treatment of uncontrolled formation of intravascular fibrin clots are provided wherein fibrinolytic or anticoagulant drugs are biocompatibly coupled to red blood cell carriers.

A microfluidic, chip-based assay device has been developed for measuring physical properties of an analyte (particularly, whole blood or whole blood derivatives). The technologies can be applied to measure clotting times of whole blood or blood derivatives, determine the effects of anticoagulant drugs on the kinetics of clotting/coagulation, as well as evaluate the effect of anticoagulant reversal agents. These technologies can additionally be used to optimize the dosage of anticoagulation drugs and/or their reversal agents. The assay is independent of the presence of anticoagulant; clotting is activated by exposure of the blood sample in the device to a glass (or other negatively charged material such as oxidized silicon) surface, which activates the intrinsic pathway and can be further hastened by the application of shear flow across the activating materials surface. The absence of chemical activating agents and highly controlled and reproducible micro-environment yields a point of care universal clotting assay.

The invention provides a preparation method of Warfarin anticoagulant drugs. The method comprises the following steps: adding main materials and adjuvants to a 3D printer and conducting 3D modeling by virtue of a computer; then, transmitting 3D modeling data to the 3D printer; conducting hierarchical slicing treatment by virtue of software of the 3D printer and forming corresponding codes; squeezing the main materials and the adjuvant materials out of a nozzle in a mode of hot-melt extrusion; conducting single-layer printing through X-axle and Y-axle motion of a printing head of the 3D printer on plane; and along with layer-by-layer accumulating and mutual bonding of the printer, completing preparation of the Warfarin anticoagulant drugs.

The invention relates to an occluder for occluding a left aurcle. The novel left aurcle occluder comprises a left aurcle packing column of the occluder, upper barbs of the left aurcle packing column of the occluder, a fixed steering connecting device, a left aurcle cover plate of the occluder, a blood flow barrier membrane, and the like. The novel left aurcle occluder is implanted into the human body by utilizing a minimally invasive therapy method and used for preventing the forming of a thrombus in the left aurcle of a patient with atrial fibrillation by occluding the left aurcle, so that the risk that long-term disability or death due to thromboembolism happens to the patient with atrial fibrillation is lowered. Meanwhile, long-term dependence of the patient with atrial fibrillation on anticoagulant drugs can be eliminated by occluding the left aurcle to provide a new treatment choice for the patient. The occluder is woven by nickel-titanium alloy wires, has a preset extensional appearance, and is used for connecting the left aurcle packing column of the occluder with the left aurcle cover plate of the occluder by virtue of the fixed steering connecting device; the upper barbs of the left aurcle packing column of the occluder are woven on the left aurcle packing column, and the blood flow barrier membrane is sewn in the left aurcle cover plate of the occluder. The novel left aurcle occluder can be used for occluding and blocking the blood flow from entering the left aurcle, the whole left aurcle occluder is smooth and flat in surface and beneficial to epithelization after being implanted.

The invention discloses a blood purification membrane with an anticoagulant property and a preparation method thereof. The blood purification membrane comprises a matrix, a polydopamine layer attachedto the surface of the substrate, argatroban grafted on the polydopamine layer and glutathione. The whole surface modification process is simple in experimental conditions, has strong controllability,and is economical and environmentally-friendly; the high-efficiency anti-coagulation on the local part of a material is realized; the blood coagulation system of a body is not affected; the blood compatibility is significantly improved; and the grafted anticoagulant drug argatroban has no antigenicity and does not cause heparin-induced thrombocytopenia.

The invention discloses a novel ancylostoma caninum anticoagulation peptide and an encoded sequence thereof and a preparation method for the anticoagulation peptide. The anticoagulation peptide acquired by the method possesses of anticoagulation activity, can markedly prolong the plasma prothrombin time (PT) and the activation part thrombozyme time(aPTT) of people and has obvious anti thrombosis effects. The invention also relates to applications of the anticoagulation peptide on aspects of anticoagulation drugs, antithrombotic drugs or anticoagulation preparations.

The invention discloses a bioconversion mycelium medium, bioconversion mycelium and a bioconversion mycelium extract, the bioconversion mycelium medium is produced by adding traditional Chinese medicine earthworm into an agricultural and sideline product culture medium, the bioconversion mycelium is a product obtained by inoculating hericium erinaceus into the bioconversion mycelium medium for mycelium conversion culture, the bioconversion mycelium extract is a product obtained by water extraction treatment, and the bioconversion mycelium extract has anticoagulation effect which is obviously better than the anticoagulation effect of hericium erinaceus mycelium or earthworm, and can be used for the preparation of anticoagulant drugs.

The invention provides a method for preparing the 1,6-Anhydro-2-azido-2-deoxy-beta-D-glucopyranose. At a room temperature, 2-Amido-2-deoxy-D-glucopyranose hydrochloride serves as a raw material, imidazole-1-sulfonyl azide hydrochloride serves as a nitrine reagent, a dowex1X8 resin serves as a acid-binding agent for acylation, silylation and sulfonylation, 1,8-Diazabicyclo-(5,4,0) undec-7-ene or the dowex1X8 resin serves as an alkali reagent for ring closing reaction, and the 1,6-Anhydro-2-azido-2-deoxy-beta-D-glucopyranose is synthesized through nitrine introduction, acylation reaction, silylation reaction, sulfonylation reaction and ring closing reaction in sequence; and the reaction process is represented as formula (I). The 1,-Anhydro-2-azido-2-deoxy-beta-D-glucopyranose can serve as an intermediate for synthesizing anticoagulant drug fondaparinux sodium. The method for preparing the 1,6-Anhydro-2-azido-2-deoxy-beta-D-glucopyranose has the advantages of being mild in reaction, simple in synthetic route, low in cost, safe and reliable, and suitable for large scale production.

The invention discloses a biodegradable intravascular stent with a composite coating. The biodegradable intravascular stent comprises a stent body and a multifunctional composite layer, wherein the multifunctional composite layer sequentially comprises a porous transition layer, a dopamine polymer layer, an anticoagulant drug layer, an endothelial regeneration promotion cell factor layer and a copper ion sterilization layer from inside to outside; the porous transition layer is prepared from the following raw materials in parts by weight: 20-30 parts of nano-silica, 0.1-0.2 part of vanillic aldehyde and 0.1-0.2 part of thymol. The biodegradable intravascular stent is scouring-resistant and stable, and has strong ability of capturing endothelial tissue cells in vitro, thus achieving the aims of well inhibiting thrombosis and reducing restenosis; therefore, the biodegradable intravascular stent has important clinical application value.

The invention discloses a left auricle occluder assembly capable of repeated contracting and releasing and an intervention method thereof. The assembly comprises a step-type saccule and an occluding amplatzer, a left auricle opening plugging part of the saccule is used for completely plugging a left auricle opening, and a left atrium anchoring part of the saccule is used for being connected to theleft atrium wall in a clamped mode and preventing the occluder from moving. The occluding amplatzer is released in the pericardium, and the rod part of the occluding amplatzer is connected and fixedto the saccule, so that the left auricle is squeezed and sealed between the saccule and the occluding amplatzer. According to the left auricle occluder assembly capable of repeated contracting and releasing and the intervention method, the left auricle opening is plugged by means of the saccule, the surface of the saccule is smooth, and the saccule is coated with anticoagulant coating; various types of left auricles can be blocked by means of the occluder assembly, thrombus formation can be prevented, and it is unnecessary to use an anticoagulant drug after operation.

This invention is about a functional after-operation isolation membrane and method for making same. The functional after-operation isolation membrane is composed of the drugs taken by biodegradable isolation membrane host material, and the drugs contain antiphlogiston drugs, fibrin inhibitor drugs, calcium channel inhibitor drugs, anticoagulant drugs and antibiotics drugs or one or several kinds of Chinese patent drugs; while the isolation membrane host material is made of one or several kinds degradation rate differed materials, whose half-decay times are 1 week to 6 months. Alerting membrane materials kinds and charging amount, drugs kinds and charging amount and isolation membrane layers can make multifunctional, degradation rate different and drug-release characteristic different functional after-operation isolation membrane products, so as to adapt to different using demands. Experiments prove that this functional after-operation isolation membrane can effectively accelerate tissue healing after operation, diminish infection and prevent after-operation adhesions.

The invention provides a composite drug-loaded fiber for an absorbable surgical suture. The existing absorbable surgical suture has few varieties and has the defects that the natural absorbable surgical suture has low strength and has the risk of generating rejection reaction, and the in-vivo degradation time of the synthesized absorbable surgical suture is too long. In order to solve the problems, the invention provides the composite drug-loaded fiber for the absorbable surgical suture, so as to make up the defects of the existing suture, avoid the pain of a patient during postoperative suture removal and reduce the infection risk. The drug-loaded fiber is prepared by compounding a main material, a reinforcing material, a pore-foaming agent, a coating material and an anti-inflammatory, antibacterial and anticoagulant drug and combining the processes of spinning, coating and the like. The fiber provided by the invention has the beneficial effects that the surface structure is uniform and smooth; the diameter is adjustable and controllable; the fiber has a porous internal structure; the fiber has good mechanical strength, extensibility, toughness and tensile property; the fiber hasexcellent biocompatibility; the fiber has more ideal in-vivo degradation time; and the fiber has good drug slow release performance, and the effects of early anti-inflammatory, antibacterial or anticoagulant of wound suture are achieved.

The invention relates to a production process of effectively extracting heparin sodium. According to the production process, with the valence of a heparin sodium final product as an index and porcine intestinal mucosa as a raw material, heparin sodium (anticoagulant drug) with high valence is extracted through a production process method comprising the steps of enzymolysis, resin adsorption/elution, membrane separation, ethanol precipitation and drying. Compared with the traditional method comprising the steps of salt resolving, ion exchange and ethanol precipitation, the method disclosed by the invention has the advantages that an enzymolysis and membrane separation technology is effectively combined with a precipitation technology so that the valence of the extracted heparin sodium can be effectively increased to 160 U/mg and improved by nearly 64 percent, and the final recovery rate is improved by 29 percent. Meanwhile, a subsequent refining process can be shortened, the production cost is reduced, and the separation yield and the separation efficiency of heparin sodium can be improved.

The invention relates to double-network structure composite hydrogel. Gelatin nano-colloidal particles form a first colloidal gel network under the electrostatic interaction and the hydrogen-bond interaction, and fibrinogen in iPRF forms a second gel network under the thrombin action. The double-network structure composite hydrogel provided by the invention is prepared by the following steps: adding a non-anticoagulation medicine in a fresh blood sample, wherein the blood can be derived from an autologous or allogeneic implanted patient; taking all on a top layer after low-speed centrifugal operation and blending the yellow liquid with gelatin particle dry powder; injecting the mixture into a mold for molding or in a tissue defect site to realize tissue filling; and waiting for not more than 2000 seconds at room temperature or body temperature to perform complete solidification to obtain a hydrogel biological medical material which has a double network structure and enhanced strength and toughness. The preparation method provided by the invention is simple and convenient and is favorable for clinical promotion. The double-network structure composite hydrogel is a regenerated, ideal, injectable and moldable biological medical material for human tissue and organ defect reconstruction.

The invention discloses thiol-ene click chemistry based preparation and characterization of fatty acid modified heparin. A preparation method comprises steps as follows: two compounds including sulfhydrylated fatty acid and a double-bond heparin-allyl conjugate are synthesized respectively, sulfydryl in the sulfhydrylated fatty acid and double bonds in the heparin-allyl conjugate are enabled to be subjected to a reaction with thiol-ene click chemistry, and then fatty acid is linked to a heparin structure, so that a fatty acid modified heparin conjugate modified with different long-chain saturated fatty acids is prepared. The invention further discloses characterization for fatty acid modified heparin on the basis of nuclear magnetic resonance hydrogen spectrum detection, anti-Xa activity determination, elemental analysis, grain-size analysis and gel permeation chromatography molecular-weight determination. According to advantages and characteristics of the thiol-ene click chemistry reaction, the long-chain saturated fatty acids are applied to heparin structure modification for the first time, anticoagulant activity of heparin is reserved, so that a new idea is provided for heparin modification, and the preparation and the characterization have great significance in research and development of novel long-acting heparin anticoagulant drugs.

The invention discloses a primer set capable of synchronously detecting related gene polymorphism of an anticoagulant drug. The primer set comprises a PCR amplification primer and a SNaPshot PCR primer; the detected sites include VKORC1-1639>A, CYP4F2*3, CYP2C9*3, CYP2C19*2, CYP2C19*3 and CYP2D6*10. Compared with a general method for individually amplifying a plurality of sites, the primer used for detecting has the advantages that the amplification processes are decreased, and the amplification cost is reduced; ,moreover, the high sensitivity, the high accuracy and the high precision can be ensured, the method reliability is ensured, and a doctor can accurately select drugs for patients and reasonably adjust the dosage of the drug.

The invention discloses a method for preparing a drug-loading aortic valve based on 3D printing and the drug-loading aortic valve, aiming at solving the technical problems of an existing valve replacement technique which requires anticoagulant therapy for a long time and is poor in durability. The method comprises the following steps: acquiring medical image data of the aortic valve; on the basis of the acquired medical image data of the aortic valve, establishing an aortic valve three-dimensional model; on the basis of the aortic valve three-dimensional model, forming a drug-loading aortic valve real body through 3D printing, wherein the drug-loading aortic valve real body comprises a valve ring real body and valve leaflet real bodies; forming drug-loading layers having drug-loading porous structures on the valve leaflet real bodies of the drug-loading aortic valve real body through 3D printing; and by virtue of a micro-droplet jetting technique, jetting anticoagulant drugs into the drug-loading porous structures of the drug-loading layers and jetting growth factors into the regions, except for the drug-loading porous structures, of the drug-loading layers, so as to form the drug-loading aortic valve. The printed aortic valve has a drug sustained-release function, the aortic valve is highly bionic and is capable of improving biocompatibility.